RALEIGH, N.C., Feb. 23, 2011 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA), a Raleigh, North Carolina biopharmaceutical drug development company, has been selected by MDB Capital Group as a 2011 "Best & Brightest" company and a "Company to Watch."
"Being chosen as a 'Best & Brightest' (BB) Company is recognition of the extraordinary work we are doing in developing new medicines to treat some of the most life-threatening diseases and debilitating chronic conditions, which we hope will result in a healthier tomorrow. Everyone at DARA BioSciences is honored by our company's selection," said Richard A. Franco, CEO/President of DARA BioSciences. Prior to co-founding DARA BioSciences in 2003, Mr. Franco was co-founder of LipoScience, Inc., senior strategist for a multi-national pharmaceutical giant, and an entrepreneur.
Christopher Marlett, CEO of MDB Capital Group, commended the DARA BioSciences management team by saying, "The Company's imbedded IP value and demonstrated innovation places it in the top 10% of the approximately 1500 technology companies trading below $500MM in market value as ranked by our proprietary IP intelligence database called PatentVest. Our research has shown that this elite group of companies demonstrating above average PatentVest metrics, such as PatentVest Tech Score and the compound annual growth rate (CAGR) of patent applications, has significantly outperformed their publicly traded peers. In addition, companies in this group have demonstrated higher margins and more sustained growth."A link to the PatentVest report can be found at MDB Capital Group's website at www.mdb.com . DARA currently has two drugs in clinical development that have the potential to help people with cancer and diabetes. KRN5500 has successfully completed a Phase 2 study for the treatment of neuropathic pain and is in partnership with the National Cancer Institute to study the treatment and prevention of chemotherapy induced peripheral neuropathy in cancer patients. DB959 has completed its first Phase I clinical study and plans to start a second in Q1 2011 for the treatment of type 2 diabetes potentially without having the side effects from other medicines now being used.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV